查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1133475

紅色生物技術全球市場-2022-2029

Global Red Biotechnology Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

紅色生物技術市場的增長受到慢性病患病率上升、老年人口增加、靶向治療的研發活動、醫療保健系統的快速擴張以及生物製劑技術進步的推動。

增加對慢性病和罕見病的補貼有望推動市場增長

癌症和心血管疾病等各種疾病的患病率上升預計將在預測期內提振市場。根據《2021 年罕見病數據報告》，世界衛生組織 (WHO) 報告稱，罕見病是一種終生疾病或紊亂，其發生頻率為千分之一或更少。在美國，罕見病被定義為影響該國少於 200,000 人（每 10,000 人中有 6.4 人）的疾病或病症。在歐盟，罕見病被定義為危及生命或長期使人衰弱的疾病，其影響不到 10,000 人中的 5 人。在日本，罕見病被定義為在日本影響不到 50,000 人（0.04%）的疾病。

此外，NICE（美國國家健康與護理卓越研究所）將在 2021 年發布最終指南，每個機構都在努力資助罕見病。新加坡為治療三種罕見病的五種藥物啟動了罕見病基金，而馬來西亞和澳大利亞則為符合條件的患者提供了高成本救命藥物的補貼。此外，就慢性病而言，據 CDC 稱，美國每年 3.8 萬億美元的醫療保健費用中有 90% 可以分配給患有慢性病和精神疾病的人。 《慢性病對策》出版物最近的一項合作研究發現，到 2030 年，治療七種主要慢性病，再加上生產力損失，每年將使美國經濟損失 2 萬億美元，即每人 8,600 美元。已決定增加對罕見病和慢性病的補貼將推動全球紅色生物市場。

對罕見病認識不足阻礙市場增長

但是，對於罕見病，早期診斷是一項重大挑戰，原因有很多，包括初級保健從業人員缺乏認識以及缺乏篩查和診斷設施。此外，患者數量有限，難以開發新藥。這是紅色生物技術市場的限制因素。

COVID-19 影響分析

COVID-19 的出現對全球紅色生物技術市場產生了重大影響。在 COVID-19 大流行期間，生物技術公司需要大力支持傳染病研究。許多 COVID-19 候選疫苗和 800 多項各種治療方法和疫苗的臨床試驗都是由在傳染病領域沒有經驗的公司開發的。顯然，這些產品和公司中沒有多少會在開發、資金或監管方面取得成功。 BIO 首席執行官 McMurry-Heath 也指出，由於 COVID-19 疾病的複雜性，多種藥物機制都可以發揮作用。這種新的關注點開始以新療法和候選疫苗的形式結出碩果。同時，COVID-19 大流行為世界各地的生物技術人員提供了獨特的機會。世界正在尋求生物技術部門開發有效的解決方案，以幫助人類對抗和控制這場危機。此外，包括研究機構、政府機構和製藥公司在內的生物技術行業正在共同努力開發檢測工具、藥物和疫苗，以應對這場衝突。因此，生物技術已成為抗擊 COVID-19 的重要參與者。包括 Zydus Cadila、Serum Institute、Biological E、Bharat Biotech、Indian Immunologicals 和 Mynvax 在內的六家印度公司正在努力開發 COVID-19 疫苗，以快速應對這種在世界範圍內迅速傳播的致命疾病。全球努力開發預防方法。

全球紅色生物技術市場報告將提供對大約 60 多個市場數據表、55 多個數字和 250 頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品類型劃分的市場細分
  • 按應用劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 慢性病發病率不斷上升
      • 研究活動增加
    • 約束因素
    • 技術和機械成本高
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 血液製品
  • 轉基因藥物
  • 人體疫苗
  • 診斷試劑
  • 個性化醫療
  • 其他

第 8 章. 按應用程序

  • 藥物基因組學
  • 生物製藥製造
  • 基因檢測
  • 基因治療

第 9 章，最終用戶

  • 研究所
  • CMO·CRO
  • 生物製藥公司
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 按地區分列的關鍵指標
      • 巴西
      • 阿根廷
      • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 12 章公司簡介

  • Hoffmann-La Roche, Ltd.
    • 公司概況
    • 治療類型組合和描述
    • 主要亮點
    • 財務摘要
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Biogen Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Company Ltd.
  • Gilead Sciences, Inc.
  • Celgene Corporation

第 13 章全球紅色生物技術市場-DataM

簡介目錄
Product Code: DMMD5856

Market Overview

Red Biotechnology Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Red biotechnology indicates biopharmaceuticals. It involves the use of biotechnology in the medical field. It covers applications of biotechnology relating to clinical trials, vaccine development, disease research, antibiotic production, drug development, and molecular diagnostics.

Market Dynamics

The red biotechnology market growth is driven by the rise in prevalence of chronic disease, increase in the geriatric population, research and development activities for targeted therapies, rapid expansion in the healthcare system and technological advancements in biologics.

The rising funding for chronic and rare diseases is expected to drive the market growth

The rising prevalence of different diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. As per the 2021 rare disease data report, the World Health Organization (WHO) reports that a rare disease is a lifelong disease or disorder with a frequency of 1 or less per 1000 populations. In the United States, rare diseases are considered diseases or conditions that affect fewer than 200,000 patients in the country (6.4 in 10,000 people). The EU identifies rare diseases as life-threatening or chronically exhausting conditions affecting no more than 5 in 10,000 people. Japan defines rare diseases as diseases with fewer than 50,000 prevalent cases (0.04%) in the country.

In addition, the various authorities take initiatives for funding for rare diseases, such as in 2021, the National Institute for Health and Care Excellence (NICE) publication of final guidance. In Singapore, a rare disease fund was created to fund five medicines to treat three rare disease conditions, and in Malaysia and Australia, subsidised access for eligible patients is offered for high-cost and lifesaving drugs. Moreover, in the case of chronic diseases, according to the CDC, 90% of the nation's $3.8 trillion per year healthcare costs can be allotted to people with chronic diseases and mental health conditions. A recent collaboration to fight chronic disease publication decided that treatment of the seven major common chronic diseases, coupled with productivity losses, will cost the U.S. economy 2 trillion dollars annually, or USD 8,600 per person by 2030. Increasing the funding for rare and chronic diseases will boost the red biotechnology market worldwide.

The lack of awarenees of rare diseases will hamper the growth of the market

However, in the case of rare diseases, early diagnosis is the main challenge due to many factors, such as lack of awareness in primary care health care professional and lack of facilities for screening and diagnosis. In addition, it is difficult to develop a new drug due to a limited patient pool and the challenge becomes more greater when rare diseases are chronic in nature, where long-term stability is required. This factor limiting the red biotechnology market groeth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global red biotechnology market. During the COVID-19 pandemic, there was a massive pivot by biotechnology companies to follow infectious disease research. Many of the COVID-19 vaccine candidates and over 800 clinical trials for various treatments and vaccines were under development by companies without prior experience in the infectious disease area. Clearly, not many of these products and companies will receive development, funding, or regulatory success. In addition, McMurry-Heath (CEO of BIO) mentioned that the complexity of COVID-19 disease has allowed a role for multiple types of drug mechanisms to be effective. They have only started to see the results of this new focus in terms of new therapeutics and vaccine candidates. On the other hand, the COVID-19 pandemic provides a unique opportunity to biotechnologists across the globe. The world is looking toward the biotech sector to develop effective solutions that will help human beings fight and control the crisis. Furthermore, research organizations, government agencies, and biotech industries, including pharmaceutical companies, have collaborated to fight this conflict by developing detection tools, medicines, and vaccines. Biotechnology has thus turned up as a superior in the fight against COVID-19. Six Indian companies, including Zydus Cadila, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax, were working on a vaccine for COVID-19, contributing to global efforts to develop a quick preventive for the deadly infection spreading rapidly across the world.

Segment Analysis

The biopharmaceutical industries segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The biopharmaceutical industry segment is expected to boost the market over the period of the forecast. This is owing to the increased approval of different therapies for diseases such as cancer. Biopharmaceuticals are pharmaceuticals drugs that are developed by using biotechnology. Biopharmaceuticals include DNA, RNA, proteins, antibodies, or antisense oligonucleotides used for therapeutic or diagnostic purposes. A growing number of new therapies for cancer and other diseases are being introduced as a result of advanced technology and the development of novel drugs. For instance, in 2020, Tecartus was approved for mantel cell lymphoma and acute lymphocytic leukemia in the US, UK, and EU by Gilead, and in 2021, Abecma was approved for multiple myeloma in the US, Canada, EU, UK, and Japan by Bluebird Bio. Due to the approval of new therapies for cancer, it is easily available for treatment in the region, which boosts the market. Furthermore, the rising incidence and prevalence of chronic and other diseases and the rapid advancement of the biopharmaceutical industry are the key driving factors in the biopharmaceutical industry segment.

Geographical Analysis

North America region holds the largest market share of the global Red Biotechnology market

North America dominates the market for red biotechnology and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, healthcare spending, awareness among patients, and the availability of proper treatment for rare and chronic diseases. The approval of different gene therapies drives the market in the North American region. For instance, in 2020, a retroviral vector ex vivo was approved by the FDA for mantle cell lymphoma, and in 2021, the same vector was approved for certain types of large B-cell lymphoma. In addition, to date, the FDA has received more than 900 applications for scrutinscrutinine therapy in clinical trials. Furthermore, as per the American Society of Gene & Cell Therapy (ASGCT) 2021 report, one novel genetically modified cell therapy has been approved in 2022. Carvykti, a CAR-T cell therapy developed by Legend Biotech and Johnson & Johnson, was approved for multiple myeloma in the U.S. and EtranaDez (etranacogene dezaparvovec), an AAV5 gene therapy developed by uniQure, filed for approval in the EU and UK for hemophilia B. The launch of the new product in the United States boosts the red biotechnology market in the North American region.

Competitive Landscape

The red biotechnology market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Pfizer, Inc., Biogen Inc., Amgen Inc., AstraZeneca Plc., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., and Celgene Corporation among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the red biotechnology market globally.

For instance,

  • In August 2022, the U.S. FDA approved MYFEMBREE, developed by Myovant Sciences and Pfizer for the treatment of the management of moderate to severe pain associated with endometriosis. MYFEMBREE offers an efficient once-daily therapy option for the control of moderate to severe endometriosis-related pain.
  • In June 2022, Amgen's RIABNI (RITUXIMAB-ARRX), a biosimilar to RITUXAN (RITUXIMAB), received FDA approval for adults with moderate to severe rheumatoid arthritis.

Biogen Inc.

Overview:

Biogen finds, develops, and distributes worldwide innovative therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic areas. The company was founded in 1978 and has the leading portfolio of medicines to treat multiple sclerosis (MS), Alzheimer's disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. It also commercializes biosimilars of advanced biologics.

Treatment type Portfolio:

BENEPALI: It was approved by the European Commission (EC) in January 2016 for the treatment of adults with moderate to severe rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis. It is currently available in more than 20 countries in the Europe region and is the most recommended etanercept in the five largest European countries (Germany, UK, France, Italy, and Spain).

The global red biotechnology market report would provide access to approximately 60+ market data tables, 55+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market snippet By Application
  • 3.3. Market snippet By End User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of chronic diseases
      • 4.1.1.2. The increasing number of research activities
    • 4.1.2. Restraints:
    • 4.1.3. High cost of technology and machinery
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Blood Products*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Gene Recombinant Drugs
  • 7.4. Human Vaccines
  • 7.5. Diagnostics Reagents
  • 7.6. Personalized Medicines
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Pharmacogenomics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biopharmaceutical Production
  • 8.4. Genetic Testing
  • 8.5. Gene Therapy

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Research Institutes*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. CMOs & CROs
  • 9.4. Biopharmaceutical Industries
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. DRest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific ynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Hoffmann-La Roche, Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. Regeneron Pharmaceuticals, Inc.
  • 12.4. Pfizer, Inc.
  • 12.5. Biogen Inc.
  • 12.6. Amgen Inc.
  • 12.7. AstraZeneca Plc.
  • 12.8. Takeda Pharmaceutical Company Ltd.
  • 12.9. Gilead Sciences, Inc.
  • 12.10. Celgene Corporation

LIST NOT EXHAUSTIVE

13. Global Red Biotechnology Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us